Biosimilars - Commercial Strategies & Regulatory Guidelines
Seminar - London, United Kingdom
The generic and biosimilar medicine industries are recognised as being among the most competitive sectors in Europe, providing high-quality pro-competitive medicines to millions of Europeans. Numerous biosimilars, or follow-on biologics, have been successfully launched in many countries outside the U.S. Lower cost biosimilar versions of more complex biologic therapies, such as monoclonal antibodies, are now eagerly awaited and expected to significantly impact healthcare costs. However, residual uncertainties surrounding approval and commercial uptake could considerably influence the true potential of this market.
Organization: SMi Group
(Courtesy of Biosimilars - Commercial Strategies & Regulatory Guidelines' logo, via skiddle.com)
Biosimilars - Commercial Strategies & Regulatory Guidelines
Mon, Dec 09, 2013 - Mon, Dec 09, 2013 (8:50 am - 1:00 pm)
Holiday Inn Bloomsbury
Coram Street, London, United Kingdom
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.
